All News

British drug-delivery company Phoqus blamed "unfavourable market" conditions for meeting only its minimum target of £10 million in its initial public offering.

Celoxica, an Oxford University spin-out that makes chip design software, blamed “depressive market” conditions for the company raising less capital than it initially expected in its initial public offering

Intercell, an Austrian biotechnology company, has received a $1 million milestone payment from Merck for progress in the development of a bacterial vaccine candidate.

Nanonucleant, a spin-out of Imperial College London, is seeking angel financing to move ahead with a glass grain-based technology that aids in crystallising proteins for study as drug targets.

Jo Taylor, head of venture capital at 3i Group, argues that universities are too quick to hit the spin-out button.

US biotechnology firm DOR BioPharma plans to build a bigger force in gastro-intestinal medicines by buying Copenhagen-based Gastrotech Pharma, a spin-out of Gothenburg University in Sweden.

With an estimated 400 million people at risk for developing dementia, a natural remedy would be a welcome answer. That's the approach one British company is taking.

"Basic research may seem very expensive. I am a well-paid scientist. My hourly wage is equal to that of a plumber..." Albert Szent-Györgyi, Nobel-winning chemist

The University of Cambridge is considering whether to make more cash available to invest in campus spin-off companies. And whatever decision it makes will come in for criticism…

Shares in Oxford BioMedica, an Oxford University spin-out, fell 8.3 percent on news that the company was seeking up to £30 million to fund the Phase III trial of its a TroVax cancer immunotherapy product.

Universities are funding more campus companies. Richard L. Hudson on the rules of a very risky game.

Chewing gum, underwater robots and other technologies, at a UK investor showcase

If you want to lead innovation in R&D, don’t neglect the crucial human factor, says Georges Haour from the IMD in Lausanne, Switzerland.

Cambridge Antibody Technology Group Plc, which is traded on both the LSE and Nasdaq markets, said an agreement was struck at the 11th hour over a royalty dispute with Abbott Laboratories Inc.